HELP Therapeutics

Focus: HELP Therapeutics is a China-based biotech specialist in induced pluripotent stem cell (iPSC) therapies and stem cell services, founded in 2016 and currently at Series C+ stage. The company operates at the frontier of regenerative medicine with a focus on cell therapy applications across cardiovascular and neurological indications.

Cell Therapy

Profile data last refreshed 19h ago · AI intelligence enriched 1w ago

Funding Stage

SERIES C +

Open Jobs

About HELP Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow HELP Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthSolid

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Nutritional educational intervention

Malnutrition

N/A

Clinical Trials (1)

NCT06195098The Tany Vao Project.

N/A

Help build intelligence for HELP Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Access to cutting-edge iPSC technology platform with multiple Phase 1/2 programs in cardiovascular disease, including HiCM-188 and hiPSC-CM therapies addressing unmet needs in heart failure
Opportunity to contribute to early-stage cell therapy commercialization in a therapeutic area (regenerative medicine) with high long-term growth potential and limited competition
Founded in 2016 with Series C+ funding, providing exposure to a company transitioning from R&D-stage to clinical-stage development with career progression visibility

Watch Out For

Pipeline data quality is severely compromised—includes non-drug entries (awareness campaigns, educational interventions, support groups), making true program count and clinical depth unclear
Currently zero active job openings listed despite Series C+ stage; China-based headquarters may limit visa sponsorship (H1B status unknown) and create geographic constraints for international candidates
No published financials, revenue data, cash position, or R&D spending available; inability to assess runway, burn rate, or long-term stability raises execution risk

Generated by Claude from HELP Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Cold-dry air provocation

Vasomotor Rhinitis

N/A

Clinical Trials (1)

NCT00415493Nasal Physiologic Reactivity of Nonallergic Rhinitics to Cold Air Provocation

N/A

Supportive-expressive group therapy

Breast Neoplasms

N/A

Clinical Trials (1)

NCT02934815Relational and Emotional Mechanisms of a Supportive-expressive Group Intervention in Breast Cancer

N/A

Nationwide Awareness Campaign and Call for Dental Screening for HHT in Germany

Hereditary Hemorrhagic Telangiectasia

N/A

Clinical Trials (1)

NCT03549949Nationwide Awareness Campaign and Call for Dental Screening for HHT in Germany

N/A

Family Supportive Supervisor Training 2.0

Psychosocial Deprivation

N/A

Clinical Trials (1)

NCT05080426Family Supportive Supervisor Training and Workplace Assessment Tool

N/A

list of resources for grief

Bereavement

N/A

Project ICARE

HIV Infections

N/A

Clinical Trials (1)

NCT00712088Project ICARE: Intervening for Community Awareness, Respect, & Empowerment

N/A

Improved Accessibility to the Renal Transplant List

Chronic End Stage Renal Failure

N/A

Clinical Trials (1)

NCT03934554Improved Accessibility to the Renal Transplant List

N/A

Organizational Partnerships

HIV

N/A

Clinical Trials (1)

NCT06171919Improving HIV Care Continuum Outcomes Among Formerly Incarcerated Individuals Through Critical Time Legal Interventions

N/A

Target Trial Emulation for Pharmacologic Treatment of Neonatal Opioid Withdrawal Syndrome

Neonatal Opioid Withdrawal Syndrome

N/A

Chronic Lymphocytic Leukemia Registry Study - Multicenter Prospective National Study

Chronic Lymphocytic Leukemia

N/A

Clinical Trials (1)

NCT03197259Chronic Lymphocytic Leukemia Registry Study - Multicenter Prospective National Study

N/A

hiPSC-CM therapy

Cardiovascular Diseases

PHASE_1

Clinical Trials (1)

NCT04982081Treating Congestive HF With hiPSC-CMs Through Endocardial Injection

Phase 1

Human

Ischemic Heart Failure

PHASE_1

Clinical Trials (1)

NCT05566600Allogeneic iPSC-derived Cardiomyocyte Therapy in Patients With Worsening Ischemic Heart Failure

Phase 1

Human Umbilical Cord-derived Mesenchymal stem cell

Osteoporosis in Post-menopausal Women

PHASE_1

Clinical Trials (1)

NCT06949137Intravenous Infusion of Human Mesenchymal Stem Cells (HMM910 ) in Postmenopausal Women With Osteoporosis at High Risk of Fracture

Phase 1

hiPSC-CM therapy

Heart Failure

PHASE_1_2

Clinical Trials (1)

NCT05223894Treating Heart Failure With hiPSC-CMs

Phase 1/2

HiCM-188 Chitosan Patch

Ischemic Heart Failure

PHASE_1_2

Clinical Trials (1)

NCT07471698hiPSC-CMs-loaded Chitosan Patch to Treat Severe Chronic Ischemic Heart Disease

Phase 1/2

low dose CABG+iPSC-CMs

Heart Failure

PHASE_1_2

Clinical Trials (1)

NCT06866600IPSC-CMs Combined with LVAD or CABG for the Treatment of Heart Failure

Phase 1/2

HiCM-188 therapy

Heart Failure

PHASE_1_2

Clinical Trials (2)

NCT07496372A Pivotal Clinical Trial of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes Injection (HiCM-188) for the Treatment of Advanced Heart Failure(NYHA III-IV)

Phase 3

NCT06340048Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure

Phase 1/2

hPSC-CM Therapy

Heart Failure

PHASE_1_2

Clinical Trials (1)

NCT03763136Treating Heart Failure With hPSC-CMs

Phase 1/2

WIN-1001X

Parkinson Disease

PHASE_2